Nebulised racemic adrenaline in the treatment of acute bronchiolitis in infants and toddlers.
The effect of inhaled nebulised racemic adrenaline upon symptoms of acute bronchiolitis was investigated in 29 infants and toddlers aged 2-17.5 months by transcutaneous oxygen tension (TcPO2), oxygen saturation, transcutaneous carbon dioxide tension (TcPCO2), and clinical evaluation in a double blind placebo controlled study. Clinical score and TcPO2 improved significantly at 30, 45, and 60 minutes after inhalation of racemic adrenaline, with an increase in TcPO2 > or = 0.5 kPa in 72% of the children < 1 year of age. No significant improvement was observed after inhalation of placebo. No significant changes in heart rate or TcPCO2 were observed from before to after inhalation, but a small increase in mean systolic blood pressure was observed immediately and 45 minutes after racemic adrenaline inhalation. This study demonstrates that treatment with nebulised racemic adrenaline improved oxygenation and clinical signs in hospitalised children aged less than 18 months with bronchiolitis.
Kristjánsson
S
S
Department of Paediatrics, Ostra Hospital, Gothenburg University, Sweden.
Lødrup Carlsen
K C
KC
Wennergren
G
G
Strannegård
I L
IL
Carlsen
K H
KH
D000208:Acute Disease; D000280:Administration, Inhalation; D001785:Blood Gas Monitoring, Transcutaneous; D001794:Blood Pressure / Q000187:drug effects; D001988:Bronchiolitis / Q000097:blood / Q000188:drug therapy*; D004837:Epinephrine / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D064705:Racepinephrine; D013997:Time Factors
D064705:Racepinephrine; D004837:Epinephrine